Physician profile
Gus C Pendleton
NPI 1649361874
$1,539.47
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $385 · 2021: $598 · 2022: $15.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $250.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $232.67 | 2019-2021 | |
| Lilly USA, LLC | $140.10 | 2020-2021 | |
| Pfizer INC. | $109.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $91.76 | 2019-2021 | |
| Tactile Systems Technology INC | $85.33 | 2021 | |
| Novo Nordisk INC | $74.97 | 2019-2021 | |
| Dynavax Technologies Corporation | $64.01 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $59.20 | 2020-2021 | |
| Boston Scientific Corporation | $57.53 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $48.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.83 | 2020-2021 | |
| Abbvie INC. | $40.37 | 2021 | |
| Allergan, INC. | $33.26 | 2019 | |
| Amarin Pharma, INC. | $32.54 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $25.68 | 2019 | |
| Janssen Biotech, INC. | $25.36 | 2019 | |
| Quidel Corporation | $23.92 | 2020 | |
| Sanofi Pasteur INC. | $18.15 | 2019 | |
| Nevro Corp. | $17.54 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.68 | 2019 | |
| Daiichi Sankyo INC. | $11.53 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gus Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.